Phase 3 N=50 Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
Sepsis Syndrome
Primary: Induction of MDSCs — 0.19; 0.11 fold change compared to baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=438 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
Functional Constipation · Irritable Bowel Syndrome With Constipation
Primary: Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention…
Phase 3 N=334 A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment — 9.7; 7.6 Months — p=0.0054
Phase 3 N=169 Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)
Nasal Polyps
Primary: Mean Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 - ITT Population Excluding Medipharma Managed Sites — -0.62; -0.19 Scores on a Scale…
Phase 3 N=16 A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Diseases (PID)
Primary: Epoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771 — 9.372; 8.741; 8.929; 9.150 grams/Liter (g/L)
Phase 3 N=71 A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
Chronic Spontaneous Urticaria
Primary: Number of Participants With Treatment Emergent Adverse Events — 62; 0; 3; 1 Participants
Phase 3 N=10 The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Absorption of Wet Weight/Fluids — 841.6; 1240.0 g/day — p== 0.0585
Phase 3 N=139 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Non-Hodgkin Lymphoma
Primary: Percentage of Participants With Administration-Associated Reactions (AARs) — 1.1; 3.7; 1.6; 1.1 Percentage of Participants %
Phase 3 N=281 Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Psoriatic Arthritis
Primary: Number of Participants With Adverse Events — 5; 14; 36; 44 Participants
Phase 3 N=43 A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
Hypertension, Pulmonary
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 22 Participants
Phase 3 N=81 Pilot Trial: Postoperative Opioid-free Analgesia
Outpatient Surgery · Abdominal Surgery · Breast Surgery
Primary: Percentage of Screened Participants Who Were Eligible to Participate in the Study — 163 Participants
Phase 3 N=233 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Invasive Candidiasis · Mucocutaneous Candidiasis · Coccidioidomycosis
Primary: Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease. — 142; 69; 22; 131 Participants
Phase 3 N=2,222 Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Urinary Tract Infections · Cystitis
Primary: Overall Success — 318; 260 Participants
Phase 3 N=102 Effect of Ertugliflozin on Cardiac Function in Diabetes
Type2 Diabetes · Heart Failure
Primary: Left Ventricular Global Longitudinal Strain (LVGLS) — 16.6; 16.4 % of LVGLS
Phase 3 N=408 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence
Platysma Prominence
Primary: Number of Participants With Adverse Events — 45; 47 Participants